Esperion Therapeutics, Inc.
NASDAQ:ESPRBiotechnology
+$0.00 today
- Market cap
- $661.15M
- Beta
- 1.07
- P/E (TTM)
- -107.3
- EPS (TTM)
- -$0.03
Volume 0.00M
Average 12.29M
ESPR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Esperion Therapeutics, Inc.NASDAQ: ESPR
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $7.84M, compared with -$1.15M a year earlier. Trailing-twelve-month accounts receivables was -$51.06M. Over 3 fiscal years it compounded at +77.2% a year.
Context
- Accounts receivables amounted to 14.9% of revenue in FY2025, up 5.4 pp from a year earlier.
- Accounts receivables grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $7.84M or moves back toward the trailing-twelve-month quarterly average of -$12.76M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (60.05M) USD
- Year-over-year change
- -89.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (60.05M) | -89.7% |
| FY2024 | 2024-12-31 | (31.65M) | -114.3% |
| FY2023 | 2023-12-31 | (14.77M) | -36.8% |
| FY2022 | 2022-12-31 | (10.8M) | -2.4% |
| FY2021 | 2021-12-31 | (10.55M) | — |
Accounts Receivables vs competitors
How ESPR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +91.4% is the 7th highest of 8, against a peer median of +207.1%.
- Accounts receivables amounts to 12.2% of revenue for ESPR, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $59.9M USD | +225.6% | -40.0% | 8.9% | |
| LTM Mar 2026 | $51.06M USD | +91.4% | +77.2% | 12.2% | |
| LTM Mar 2026 | $9.02M USD | +328.9% | — | 10.3% | |
| LTM Mar 2026 | $5.26M USD | +166.0% | -38.3% | 0.6% | |
| LTM Mar 2026 | $3.65M USD | +482.9% | — | 7.3% | |
| LTM Mar 2026 | $2.68M USD | -75.5% | -22.4% | 2.9% | |
| LTM Mar 2026 | $1.38M USD | +207.1% | — | 75.4% | |
| LTM Mar 2026 | $36K USD | +167.9% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding ESPR) | — | +207.1% | -38.3% | 7.3% | |
Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (22.68M) |
| Depreciation & Amortization | 612K | 500K | 164K | 63K | 105K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.31M | 15.22M | 11.96M | 11.99M | 9.87M |
| Change in Working Capital | (52.51M) | (3.37M) | 13.68M | (60.53M) | (14.64M) |
| Accounts Receivables | (10.55M) | (10.8M) | (14.77M) | (31.65M) | (60.05M) |
| Inventory | (18.26M) | (807K) | (30.42M) | (28.87M) | (10.63M) |
| Accounts Payables | (34.1M) | 5.6M | 8.68M | 12.43M | 20.92M |
| Other Working Capital | 10.39M | 2.63M | 50.18M | (12.45M) | 35.12M |
| Other Non-Cash Items | 32.89M | 46.49M | 47.96M | 76.57M | 14.26M |
| Operating Cash Flow | (263.81M) | (174.83M) | (135.49M) | (23.65M) | (13.09M) |
| Capital Expenditures | 0 | 0 | 0 | (317K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (50.48M) | (59.9M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 68M | 42.5M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.48M) | 8.1M | 42.5M | (317K) | 0 |
| Debt Repayment | (440K) | (58.24M) | (15.51M) | 35.01M | (54.91M) |
| Common Stock Issued | 218.69M | 90.85M | 56.88M | 91.19M | 98.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 49.98M | 0 | (6.42M) | (39.72M) | (7.26M) |
| Financing Cash Flow | 268.22M | 32.61M | 50.46M | 86.48M | 36.18M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.07M) | (134.12M) | (42.53M) | 62.51M | 23.09M |
| Free Cash Flow | (263.81M) | (174.83M) | (135.49M) | (23.97M) | (13.09M) |
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.